SMO and myeloid sarcoma: The involvement of the Hh pathway in mitigating neuroinflammation and axonal damage in MS and EAE has been previously reported, demonstrating that both genetic and pharmacological inactivations of Smo result in severe exacerbations of the clinical manifestations [20,42].